Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases 4,100 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel bought 4,100 shares of Greenwich LifeSciences stock in a transaction dated Thursday, December 18th. The stock was purchased at an average cost of $12.62 per share, with a total value of $51,742.00. Following the completion of the acquisition, the chief executive officer directly owned 5,592,202 shares in the company, valued at approximately $70,573,589.24. The trade was a 0.07% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Snehal Patel also recently made the following trade(s):

• On Tuesday, November 25th, Snehal Patel purchased 4,600 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $8.37 per share, for a total transaction of $38,502.00.
• On Friday, November 7th, Snehal Patel acquired 10,600 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $8.43 per share, with a total value of $89,358.00.
• On Friday, October 31st, Snehal Patel acquired 2,300 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $9.26 per share, with a total value of $21,298.00.

Greenwich LifeSciences Price Performance

Shares of Greenwich LifeSciences stock opened at $12.39 on Friday. The firm’s fifty day simple moving average is $9.17 and its 200-day simple moving average is $10.23. Greenwich LifeSciences, Inc. has a 12 month low of $7.78 and a 12 month high of $14.47. The stock has a market capitalization of $171.66 million, a price-to-earnings ratio of -8.49 and a beta of 1.61.

Greenwich LifeSciences (NASDAQ:GLSI) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.30). Analysts anticipate that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Greenwich LifeSciences in a research note on Tuesday, October 14th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $42.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Greenwich LifeSciences by 4.9% in the third quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock valued at $2,808,000 after purchasing an additional 13,179 shares during the period. Geode Capital Management LLC boosted its stake in shares of Greenwich LifeSciences by 1.4% in the second quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock valued at $1,261,000 after buying an additional 1,972 shares in the last quarter. Marshall Wace LLP acquired a new position in Greenwich LifeSciences during the second quarter worth $509,000. Citadel Advisors LLC raised its position in Greenwich LifeSciences by 52.1% in the third quarter. Citadel Advisors LLC now owns 20,942 shares of the company’s stock worth $208,000 after acquiring an additional 7,174 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Greenwich LifeSciences by 15.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 19,007 shares of the company’s stock valued at $181,000 after acquiring an additional 2,552 shares during the period. 4.16% of the stock is currently owned by institutional investors and hedge funds.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.